Vistide

Side Effects:

Report any fever, sore throat or infection that may develop during treatment;

as well as rash, swelling, trouble breathing, fatigue, thirst or change in amount of urine as soon as possible.

Also, report promptly any eye or ear/hearing problems.

Precautions:

Inform your prescriber if you have kidney disease, or any allergies.

Cidofovir must be used in combination with probenecid.

According to the manufacturer, if you have had a severe allergic reaction to either probenecid or sulfa drugs, cidofovir should not be used.

To avoid HIV transmission, sex practices should be discussed with your doctor.

Men should use latex condoms during and for 3 months after cidofovir treatment.

Women should use effective birth control methods during and for one month following cidofovir treatment.

This medication should be used only when clearly needed during pregnancy.

Discuss the risks and benefits with your doctor.

It is unknown if this drug is excreted into breast milk.

Avoid breast-feeding.

Generic Name: CIDOFOVIR INJECTION

Related:

Vistide 75 mg/ml Vial - Prescription

cidofovir

http://www.bt.cdc.gov/agent/smallpox/vaccination/pdf/cidofovir.pdf

vaccine, cidofovir, smallpox vaccine, reactions, virus, eye, infections, drug, protocol, immunity, VistideÆ, loss, blood cells, kidney.

The smallpox vaccine is made from a live virus related to smallpox called vaccinia (not smallpox virus).

The vaccine stimulates the immune system to react against the vaccinia virus, and develop immunity to it.

Vistide (cidofovir), a drug licensed to treat serious viral infections of the eye in HIV-infected people, may help people who have certain serious reactions to the smallpox vaccine.

VistideÆ (Cidofovir) is licensed to treat cytomegalvirus (CMV) retinitis (a serious eye infection) in HIV-infected people.

It is not licensed to treat the problems caused by smallpox vaccine so it is only available through a special protocol called an Investigational New Drug (IND) protocol.

vistide-pi

http://www.hhs.gov/ohrp/dpanel/vistide-pi.pdf

cidofovir, patients, VISTIDE, mg/kg, probenecid, administration, dose, CMV retinitis, therapy, treatment, discontinuation, resistant, infusion, creatinine clearance.

VISTIDE IS INDICATED ONLY FOR THE TREATMENT OF CMV RETINITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.

IN ANIMAL STUDIES CIDOFOVIR WAS CARCINOGENIC, TERATOGENIC AND CAUSED HYPOSPERMIA (SEE CARCINOGENESIS, MUTAGENESIS, & IMPAIR MENT OF FERTILITY).

Enrolled patients had been diagnosed with CMV retinitis an average of 390 days prior to randomization and had received a median of 3.8 prior courses of systemic CMV therapy.

Dose adjustment or discontinuation is required for changes in renal function (serum creatinine and/or urine protein) while on therapy.

The following additional list of adverse events/intercurrent illnesses have been observed in clinical studies of VISTIDE and are listed below regardless of causal relationship to VISTIDE.

mphan

http://www.cdc.gov/ncidod/monkeypox/pdf/mphan.pdf

monkeypox, smallpox vaccination, animals, infections, recommendations, outbreak, health, VIG, cidofovir, vaccination, exposure, guidance, confirmation, interim.

The principal changes include a revision of the definition of close contact with an ill animal, vaccination of clinical laboratory workers handling specimens from ill animals and persons infected with monkeypox virus, and instructions for reporting smallpox vaccine-related serious adverse events to the Vaccine Adverse Event Reporting System (VAERS).

This interim CDC guidance was developed using the best available information about the benefits and risks of smallpox vaccination, VIG, and cidofovir for prevention and management of smallpox, monkeypox and complications of vaccinia infection.

These persons have a risk of severe complications from smallpox vaccination that may approach or exceed the risk of disease from monkeypox exposure.

Pregnancy resources

Allergy resources

Skin Care

HGH file

Telephone set 1100